Company / Cash & Equivalents
Vanda Pharmaceuticals Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$84.9M
FY2025
5-year range
$52.1M / $135.8M
FY2021-FY2025
Trend
-17.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $34M in FY2017 to $136M in FY2023.
Based on SEC 10-K filings.
$85M in FY2025 with a 5-year CAGR of +6.8%.
Declined from $136M to $85M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -14.3%
- 5-Year CAGR
- +6.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.8%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 17.1% year-over-year.
- Peak cash & equivalents was recorded in FY2023.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.96 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $84.9M | -17.1% |
| FY2024 | $102.3M | -24.7% |
| FY2023 | $135.8M | +0.6% |
| FY2022 | $135.0M | +159.3% |
| FY2021 | $52.1M | -14.7% |
| FY2020 | $61.0M | +35.4% |
| FY2019 | $45.1M | -26.1% |
| FY2018 | $61.0M | +81.4% |
| FY2017 | $33.6M | -44.8% |
| FY2016 | $60.9M | -6.0% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026